Citable filing context
PFE's research view summarizes recent SEC filing context, starting with earnings from Aug 4, 2026.
| Filed | Item | Context |
|---|---|---|
| Aug 4, 2026 | earnings | Pfizer reported Q2 2026 revenues of $15.0 billion and raised its full-year 2026 revenue guidance by $500 million. |
| Jun 18, 2026 | management_change | CFO Dave Denton will step down August 15, 2026, with Cecile Guegan appointed as Interim CFO. |
| Jun 18, 2026 | guidance_update | Pfizer reaffirmed FY 2026 guidance of $59.5-$62.5 billion in revenue and $2.80-$3.00 Adjusted Diluted EPS. |
| Aug 4, 2026 | Guidance: adjusted_diluted_eps | 2.80 to 3.00 |
| Aug 4, 2026 | Guidance: revenue | 60500.00 to 62500.00 |
| Jun 18, 2026 | Guidance: adjusted_diluted_eps | 2.80 to 3.00 |
| Aug 4, 2026 | mda_quarterly | Pfizer reported second-quarter 2026 total revenues of $15.0 billion, a 3% increase year-over-year, with operational growth of 1% driven by strong performance in Eliquis, Padcev, the Vyndaqel family, and Lorbrena. Excluding COVID-19 products Comirnaty and Paxlovid, operational revenue growth reached 5%. Despite higher revenues, the company reported a loss from continuing operations of $653 million, primarily due to significant intangible asset impairments, legal charges, and increased R&D spending on oncology and obesity candidates. Management is aggressively pursuing cost-reduction initiatives, targeting $6.7 billion in net savings from its "Realigning Our Cost Base" program and $3.0 billion from its "Manufacturing Optimization Program" through 2029. Additionally, Pfizer is navigating a complex regulatory environment, including the impact of the Inflation Reduction Act’s Medicare Drug Price Negotiation Program on Eliquis, Ibrance, and Xtandi. The company also faces headwinds from patent expirations, which are expected to accelerate through 2030. To bolster its pipeline, Pfizer recently finalized a $650 million upfront collaboration with Innovent for early-stage cancer medicines. While the company maintains a stable liquidity position, it continues to monitor geopolitical risks, including potential tariff impacts and evolving global tax frameworks like the OECD’s Pillar 2. |
| May 5, 2026 | mda_quarterly | Pfizer's first quarter 2026 total revenues increased 5% to $14.5 billion, with operational growth of 2%. This was primarily driven by strong performance from Padcev, Eliquis, Oncology biosimilars, Nurtec ODT/Vydura, Lorbrena, and Abrysvo. This growth was largely offset by significant declines in COVID-19 product revenues from Comirnaty and Paxlovid; excluding these, operational revenue growth was 7%. Income from continuing operations rose to $3.2 billion, benefiting from higher revenues and reduced restructuring charges, despite increased Cost of Sales and R&D, the latter driven by oncology and obesity pipeline investments. Significant patent expiries are anticipated from 2026-2030, with a projected $1.5 billion revenue impact in 2026. The Inflation Reduction Act (IRA) is impacting Eliquis pricing from January 2026, with Ibrance and Xtandi affected in 2027. New U.S. Section 232 tariffs on imported patented pharmaceuticals, up to 100% duty, are set for July 2026, though Pfizer is negotiating an agreement. The company is executing cost-reduction programs, targeting $5.7 billion in savings by 2026 from "Realigning Our Cost Base" and $1.5 billion by 2027 from "Manufacturing Optimization," alongside $600 million in annual synergies from the Metsera acquisition. Recent developments include U.S. approval for Veppanu (ER+/HER2- breast cancer) and regulatory filings for Tukysa and Padcev. Pfizer maintains strong liquidity, recently exiting its ViiV investment for $1.875 billion, and prioritizes reinvestment, dividends, and future share repurchases after de-levering. |
Source: SEC EDGAR filing text and events; period Aug 4, 2026; filed Aug 4, 2026.
PFE company research is available with Aerarium Pro (CAD $10/mo). The five showcase tickers (TSLA, NVDA, AAPL, AMZN, PLTR) and the macro dashboard stay free. Already a subscriber? Sign in to pick up where you left off.